SolasCure demonstrates proof-of-concept in trial of new magg

Biotech company SolasCure has announced the results of its proof-of-concept phase 2 trial investigating its wound gel for chronic venous leg ulcer patients.

Related Keywords

, Andy Weymann , Rob Kirsner , Aurase Wound Gel , Bio Developments , Pipelines , Emerging Markets , Wound Healing , Drug Delivery , Formulation , Clinical Trial ,